OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
207058

Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC

PharmaceuticalsVerified

Capital Structure and Liquidity The company has a debt-to-equity ratio of 0.9, indicating a moderate level of leverage. Its liquidity position is characterized as medium, with a current ratio of 1.28, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk. ### Profitability and Returns The company's return on equity (ROE) is 11.55%, and its return on assets (ROA) is 4.22%, both of which are key indicators of profitability and efficiency in asset utilization. These figures suggest that the company is generating a reasonable return for its shareholders and effectively using its assets to generate profit. ### Segments and Geographic Exposure The company operates primarily in the pharmaceuticals segment, with no disclosed geographic revenue concentration data available. This implies that its operations are likely concentrated within Saudi Arabia, though the exact geographic distribution of its revenue is not specified. ### Growth Trajectory The company's revenue for the latest period is SAR 1.7 billion, with an operating income of SAR 266.2 million and a net income of SAR 184.4 million. While specific growth rates are not provided, the company's free cash flow of SAR 204.8 million indicates a positive cash flow generation capability, which supports potential for future growth. ### Risk Factors The company faces a medium liquidity risk, as indicated by its current ratio and negative net cash position after debt. The risk of dilution is assessed as low, with no significant dilution potential identified in the basic shares outstanding. No major adjustments have been applied to the valuation metrics, suggesting that the financial data is relatively clean and reliable. ### Recent Events There are no specific recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position.

30-day price · 2070(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySaudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC
Ticker2070.SE
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC is a pharmaceutical company that develops, produces, and distributes a range of pharmaceutical products and medical appliances.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

### Capital Structure and Liquidity The company has a debt-to-equity ratio of 0.9, indicating a moderate level of leverage. Its liquidity position is characterized as medium, with a current ratio of 1.28, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk. ### Profitability and Returns The company's return on equity (ROE) is 11.55%, and its return on assets (ROA) is 4.22%, both of which are key indicators of profitability and efficiency in asset utilization. These figures suggest that the company is generating a reasonable return for its shareholders and effectively using its assets to generate profit. ### Segments and Geographic Exposure The company operates primarily in the pharmaceuticals segment, with no disclosed geographic revenue concentration data available. This implies that its operations are likely concentrated within Saudi Arabia, though the exact geographic distribution of its revenue is not specified. ### Growth Trajectory The company's revenue for the latest period is SAR 1.7 billion, with an operating income of SAR 266.2 million and a net income of SAR 184.4 million. While specific growth rates are not provided, the company's free cash flow of SAR 204.8 million indicates a positive cash flow generation capability, which supports potential for future growth. ### Risk Factors The company faces a medium liquidity risk, as indicated by its current ratio and negative net cash position after debt. The risk of dilution is assessed as low, with no significant dilution potential identified in the basic shares outstanding. No major adjustments have been applied to the valuation metrics, suggesting that the financial data is relatively clean and reliable. ### Recent Events There are no specific recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position.
Key takeaways
  • The company has a moderate debt-to-equity ratio of 0.9, indicating a balanced capital structure.
  • It generates a return on equity of 11.55%, suggesting strong profitability for shareholders.
  • The company's liquidity position is medium, with a current ratio of 1.28.
  • Free cash flow of SAR 204.8 million indicates the company's ability to generate positive cash flow.
  • The risk of dilution is low, with no significant dilution potential in the basic shares outstanding.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$1.71B
Gross profit$832.6M
Operating income$266.2M
Net income$184.4M
R&D
SG&A
D&A
SBC
Operating cash flow$272.4M
CapEx-$89.1M
Free cash flow$204.8M
Total assets$4.37B
Total liabilities$2.77B
Total equity$1.60B
Cash & equivalents$46.0M
Long-term debt$1.43B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$1.71B$266.2M$184.4M$204.8M
FY-1$1.68B$137.5M$24.5M$42.5M
FY-2$1.66B$52.2M-$50.7M-$65.3M
FY-3$1.42B-$114.4M-$165.1M-$218.6M
FY-4$1.46B$55.5M$26.5M-$91.5M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$4.37B$1.60B$46.0M
FY-1$4.32B$1.38B$0.00
FY-2$3.88B$1.38B$33.2M
FY-3$3.83B$1.54B$123.0M
FY-4$4.43B$1.84B$67.8M
PeriodOCFCapExFCFSBC
FY0$272.4M-$89.1M$204.8M
FY-1-$331.0M-$71.3M$42.5M
FY-2$10.9M-$106.8M-$65.3M
FY-3-$99.3M-$78.2M-$218.6M
FY-4$86.7M-$82.9M-$91.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$423.8M$87.5M$65.1M$80.3M
FQ-1$405.8M$55.7M$38.8M$18.4M
FQ-2$415.3M$64.7M$42.1M$56.5M
FQ-3$400.8M$61.4M$32.6M$47.3M
FQ-4$484.8M$84.5M$70.8M$82.3M
FQ-5$386.2M$11.7M-$36.2M-$25.2M
FQ-6$447.3M$21.3M-$11.0M$10.3M
FQ-7$373.5M$31.2M$17.1M$4.9M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$4.27B$1.66B$0.00
FQ-1$4.37B$1.60B$46.0M
FQ-2$4.44B$1.55B$29.8M
FQ-3$4.51B$1.50B$86.0M
FQ-4$4.49B$1.46B$45.0M
FQ-5$4.32B$1.38B$0.00
FQ-6$4.47B$1.47B$794.0k
FQ-7$4.41B$1.48B$32.7M
PeriodOCFCapExFCFSBC
FQ0$111.4M-$10.7M$80.3M
FQ-1$272.4M-$89.1M$18.4M
FQ-2$190.1M-$50.6M$56.5M
FQ-3$110.1M-$32.6M$47.3M
FQ-4$18.4M-$17.6M$82.3M
FQ-5-$331.0M-$71.3M-$25.2M
FQ-6-$321.6M-$60.3M$10.3M
FQ-7-$212.6M-$57.7M$4.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.60B
Net cash-$1.39B
Current ratio1.3
Debt/Equity0.9
ROA4.2%
ROE11.6%
Cash conversion1.5%
CapEx/Revenue-5.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric2070Activity
Op margin15.6%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin10.8%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin48.8%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-5.2%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity90.0%71.3% medp25 19.0% · p75 91.7%above median
Observations
IR observations
Mean price target31.65 SAR
Median price target32.80 SAR
High price target33.00 SAR
Low price target28.00 SAR
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.86 SAR
Last actual EPS1.54 SAR
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 00:24 UTCJob: 192549ac